Oral contraceptives. Current status of therapy.
D000574:American Medical Association; D056486:Chemical and Drug Induced Liver Injury; D003276:Contraceptives, Oral / Q000009:adverse effects / Q000494:pharmacology / Q000502:physiology; D004702:Endocrine Glands / Q000187:drug effects; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D005298:Fertility / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007434:Intrauterine Devices; D007986:Luteinizing Hormone / Q000378:metabolism; D008881:Migraine Disorders / Q000139:chemically induced; D009461:Neurologic Manifestations; D010053:Ovary / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects; D010902:Pituitary Gland / Q000187:drug effects; D011374:Progesterone / Q000494:pharmacology; D011372:Progestins / Q000009:adverse effects / Q000494:pharmacology; D012871:Skin Diseases / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced; D013924:Thrombophlebitis / Q000139:chemically induced; D014481:United States
D003276:Contraceptives, Oral; D004967:Estrogens; D011372:Progestins; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone